Published in Cancer Weekly, October 7th, 1996
Nilandron is an oral, once-daily antiandrogen therapy for men with advanced prostate cancer. Indicated for use in combination with surgical castration (orchiectomy) for the treatment of advanced prostate cancer (cancer that has spread to other parts of the body), Nilandron has been scheduled for launching in the United States in the fall of 1996. For maximum benefit, Nilandron must be started on the same day as or on the day after surgery.
Currently, there is no cure...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.